The committee deals with JGA’s organizational management , public relations, and financial issues.
The committee deals with regulatory issues related to the approval and license of generic medicines.
The committee deals with regulatory issues related to reevaluation of approved medicines stipulated by the relevant law.
The committee is for exchanging information and knowledge on the development of pharmaceutical science, formulation technology and regulatory guidelines.
The committee deals with safety issues such as safety information, GVP(Good Vigilance Practice) and GPSP(Good Post-Marketing Study Practice).
The committee deals with quality assurance issues such as GQP(Good Quality Practice) and GMP(Good Manufacturing Practice).
The committee is for exchanging opinions on appropriate way and skill of information provision for medical professionals and patients.
The objectives of the committee include to safeguard common interests of member companies on national and international pharmaceutical IP matters and to help promote the competitiveness of the generic industry.
The committee deals with distribution issues such as further promotion of transparency in distribution and stable supply of generic medicines.
The committee deals with NHI(National Health Insurance) related matters such as drug pricing and reimbursement system, medical service fees and dispensing fees.
The committee is for exchanging and reviewing information on global generic medicine issues related to market trend, regulatory affairs, intellectual property and other business topics. The committee also promotes global collaboration with oversea generics industry associations.
The committee reviews and promotes environmental conservation activities by gathering information about trends of countermeasures against global warming and reduction of industrial wastes in cooperation with other pharmaceutical associations.
The committee aims to ensure each JGA member’s compliance with Code of Practice and Fair Competition Code.
The Committee aims to ensure each JGA member company compliant with corporate ethic code, as well as the JGA Charter of Corporate Behavior and Compliance Program Guidelines.
The area of focus included to collect and discuss information related to biosimilar medicines both from local and global sources, and provide relevant information to multiple stakeholders.
The task force is responsible for review on actions to be taken by industry side in response to the “Roadmap for Further Promotion of Generic Medicine Use”announced by the Ministry of Health,Labour and Welfare in April,2013.
This committee formulates the views of the association on the future vision of the generic pharmaceutical industry as well as on
the relevant important issues.